OctoPlus works together with SingVax , a Singapore-based vaccine development company, to co-develop a single-shot Japanese encephalitis (JE) vaccine.

Single-shot vaccine innovation
Existing JE vaccines typically require two or three doses. By creating a single-shot JE vaccine we aim to achieve increased patient compliance and greater efficacy of the vaccine. As such, it will help protect more people from this life threatening disease.

Significant market potential
We target a significant proportion of the estimated US$400 million global market for JE vaccines. To date, no single-shot JE vaccine exists that is available on an international scale.

What is Japanese encephalitis?
The JE virus causes an encephalopathy, a fever of the brain that can lead to death or severe neurological damage in survivors. According to the WHO, approximately 50,000 cases are reported in Asia annually, with approximately 15,000 deaths attributed directly to infection with JEV.